BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10086938)

  • 1. Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development.
    Annerén G; Tuvemo T; Carlsson-Skwirut C; Lönnerholm T; Bang P; Sara VR; Gustafsson J
    Arch Dis Child; 1999 Apr; 80(4):334-8. PubMed ID: 10086938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth and somatomedin responses to growth hormone in Down's syndrome.
    Annerén G; Sara VR; Hall K; Tuvemo T
    Arch Dis Child; 1986 Jan; 61(1):48-52. PubMed ID: 2937371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First two years' response to growth hormone treatment in very young preterm small for gestational age children.
    Garcia RA; Longui CA; Kochi C; Arruda M; Faria CD; Calliari LE; Monte O; Pachi PR; Saenger P
    Horm Res; 2009; 72(5):275-80. PubMed ID: 19844113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant increase of IGF-I concentration and of IGF-I/IGFBP-3 molar ratio in generation test predicts the good response to growth hormone (GH) therapy in children with short stature and normal results of GH stimulating tests.
    Smyczynska J; Hilczer M; Stawerska R; Lewinski A
    Neuro Endocrinol Lett; 2013; 34(3):222-8. PubMed ID: 23685421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of insulin-like binding protein-2 in prepubertal short children and its diagnostic value in the evaluation of growth hormone deficiency.
    van Doorn J; Ringeling AM; Rikken B; van Buul-Offers SC
    Horm Res; 2001; 55(3):147-54. PubMed ID: 11549877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of growth hormone insulin like growth factor-I axis in Down's syndrome.
    Barreca A; Rasore Quartino A; Acutis MS; Ponzani P; Damonte G; Miani E; Balestra V; Giordano G; Minuto F
    J Endocrinol Invest; 1994 Jun; 17(6):431-6. PubMed ID: 7930388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency.
    Rikken B; van Doorn J; Ringeling A; Van den Brande JL; Massa G; Wit JM
    Horm Res; 1998 Sep; 50(3):166-76. PubMed ID: 9762006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose growth hormone treatment of short children born small for gestational age.
    de Zegher F; Maes M; Gargosky SE; Heinrichs C; Du Caju MV; Thiry G; De Schepper J; Craen M; Breysem L; Löfström A; Jönsson P; Bourguignon JP; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1996 May; 81(5):1887-92. PubMed ID: 8626853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients.
    Sıklar Z; Öcal G; Berberoğlu M; Bilir P
    J Clin Res Pediatr Endocrinol; 2009; 1(5):240-3. PubMed ID: 21274301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final height and insulin-like growth factor-1 in children with medulloblastoma treated with growth hormone.
    Chae HW; Park YS; Kim DS; Kwon AR; Kim HS; Kim DH
    Childs Nerv Syst; 2013 Oct; 29(10):1859-63. PubMed ID: 23775040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHOX gene variants: growth hormone/insulin-like growth factor-1 status and response to growth hormone treatment.
    Shapiro S; Klein GW; Klein ML; Wallach EJ; Fen Y; Godbold JH; Rapaport R
    Horm Res Paediatr; 2015; 83(1):26-35. PubMed ID: 25659810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
    Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
    J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children.
    Ali A; Hashim R; Khan FA; Sattar A; Ijaz A; Manzoor SM; Younas M
    J Ayub Med Coll Abbottabad; 2009; 21(3):40-5. PubMed ID: 20929010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.